Correlation between histological subtype and type of bcl-2/IgH rearrangement in follicular lymphomas.

abstract：:The frequency of ras gene mutations varies from 11 to 27% in AML populations from the United States and Europe but it seems that there is no study regarding the frequency of mutated N-ras gene in patients with AML in South America. In order to study the frequency of N-ras gene mutations (exons 1 and 2) in Brazilian pa...

journal_title：Leukemia & lymphoma

authors： De Melo MB,Lorand-Metze I,Lima CS,Saad ST,Costa FF

更新日期：1997-01-01 00:00:00

abstract：:The long-term results of postremission chemotherapy for 122 consecutive, unselected adults (15-65 years) with acute myeloid leukemia (AML) were assessed in two sequential prospective studies involving an identical 3/7-type induction regimen, and in those achieving remission, another course for early consolidation usin...

journal_title：Leukemia & lymphoma

authors： Jehn U

更新日期：1994-09-01 00:00:00

abstract：:Chronic exposure to high concentrations of benzene is associated with an increased incidence of myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Studies of patients occupationally exposed to benzene show a pattern of cytogenetic aberrations involving loss of all or part of chromosomes 5 and/or 7 as...

journal_title：Leukemia & lymphoma

authors： Stillman WS,Varella-Garcia M,Irons RD

更新日期：1999-10-01 00:00:00

abstract：:Multidrug resistance represents an important mechanism by which leukaemic and solid tumour cells escape cell death after exposure to anthracyclines and other natural products. Acute myeloid leukaemia (AML) associated with the inversion chromosome 16: inv(16)(p13q22) has a favourable prognosis and is known to be chemos...

journal_title：Leukemia & lymphoma

authors： Kuss BJ,Deeley RG,Cole SP,Willman CL,Kopecky KJ,Wolman SR,Eyre HJ,Callen DF

更新日期：1996-02-01 00:00:00

abstract：:Analysis of the microRNA transcriptome following dexa- methasone treatment of the acute lymphocytic leukemia (ALL) cell line RS4;11 showed a global down-regulation of microRNA levels. MIR17HG was rapidly down-regulated following treatment, with chromatin immunoprecipitation (ChIP) analysis demonstrating the promoter t...

journal_title：Leukemia & lymphoma

authors： Harada M,Pokrovskaja-Tamm K,Söderhäll S,Heyman M,Grander D,Corcoran M

更新日期：2012-10-01 00:00:00

abstract：:The objective of this work was to determine the safety and efficacy of gemtuzumab ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the following diagnoses/characteristics were treated with 1-3 infusions of gemtuzumab ozogamicin at a dose of 9 mg/m2: (1) relapse of AML < or = 6 mon...

journal_title：Leukemia & lymphoma

authors： Roboz GJ,Knovich MA,Bayer RL,Schuster MW,Seiter K,Powell BL,Woodruff RD,Silver RT,Frankel AE,Feldman EJ

更新日期：2002-10-01 00:00:00

abstract：:The aim of this study was to determine the expression of Gravin (a tumor suppressor gene belonging to the A kinase anchoring protein family) in samples of acute leukaemia and to explore its association with the prognosis. The study group consisted of 162 people (137 patients with acute leukaemia and 25 volunteers as c...

journal_title：Leukemia & lymphoma

authors： Yildirim M,Paydas S,Tanriverdi K,Seydaoglu G,Disel U,Yavuz S

更新日期：2007-06-01 00:00:00

abstract：:In ninety-three cases of newly diagnosed acute myeloid leukaemia (AML) we investigated the importance to short- and long term clinical outcome of the in vitro short term leukaemia cell survival as measured by a 4-day MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide)-assay. In 67 patients treated by i...

journal_title：Leukemia & lymphoma

authors： Nørgaard JM,Jensen PD,Bendix K,Clausen N,Palshof T

更新日期：1999-01-01 00:00:00

abstract：:Even though amphotericin B is associated with considerable hematological toxicity, this subject has been poorly studied. This retrospective cohort study assessed the incidence and predictors of hematological toxicity in patients treated with different amphotericin B formulations: amphotericin B deoxycholate (d-AmB), l...

journal_title：Leukemia & lymphoma

authors： Falci DR,da Rosa FB,Pasqualotto AC

更新日期：2015-01-01 00:00:00

abstract：:Vasculitis may accompany neoplasias and be of paraneoplastic type or associated with drugs used in patient treatment. We evaluated skin biopsies of twenty-eight cases with vasculitis accompanying leukemias reviewed and clinical outcome was evaluated. Eleven of the 28 cases had paraneoplastic vasculitis and 17 had vasc...

journal_title：Leukemia & lymphoma

authors： Paydaş S,Zorludemir S,Sahin B

更新日期：2000-12-01 00:00:00

abstract：:Akt (protein kinase B) is a serine/threonine kinase involved in the regulation of cell survival signals. Akt is expressed in T- and B-lymphocytes and is activated in response to cytokine and antigen-receptor stimulation. Three isoforms of Akt have been identified, Akt-1, -2 and -3, but the expression pattern and speci...

journal_title：Leukemia & lymphoma

authors： Fillmore GC,Wang Q,Carey MJ,Kim CH,Elenitoba-Johnson KS,Lim MS

更新日期：2005-12-01 00:00:00

abstract：:We examined the effect of high-dose methylprednisolone (HDMP) on blast reduction rate and compared it to conventional dose steroid treatment, administered during the first 7+ days of the induction remission period in patients with acute lymphoblastic leukemia (ALL). In our previous randomized study, the event free sur...

journal_title：Leukemia & lymphoma

authors： Yetgin S,Cetin M

更新日期：2003-03-01 00:00:00

abstract：:Recombinant interferon alpha-2b (IFN-alpha2) has direct and indirect antiproliferative effects in lymphoma, and may augment cytotoxicity when combined with chemotherapy. CALGB 8691 is a randomized study of daily oral cyclophosphamide (CPA) at 100 mg/m2 with or without IFN-alpha2 at 2 x 106 IU/m2 three times per week, ...

journal_title：Leukemia & lymphoma

authors： Smith SM,Johnson J,Cheson BD,Canellos G,Petroni G,Oken M,Duggan D,Hurd D,Gockerman JP,Parker B,Prchal J,Peterson BA,Cancer and Leukemia Group B.,Eastern Cooperative Oncology Group.

更新日期：2009-10-01 00:00:00

abstract：:High-dose therapy (HDT) is now recommended for patients under 60 years of age with chemosensitive relapsed aggressive non-Hodgkin's lymphoma. However, approximately half of these patients will be cured by HDT. Prognostic factors are needed to predict which patients with chemosensitive lymphoma to second-line therapy c...

journal_title：Leukemia & lymphoma

authors： Jabbour E,Peslin N,Arnaud P,Ferme C,Carde P,Vantelon JM,Bocaccio C,Bourhis JH,Koscielny S,Ribrag V

更新日期：2005-06-01 00:00:00

abstract：:Whether long non-coding RNA (lncRNA) single-nucleotide polymorphisms (SNPs) affect prognosis of acute myeloid leukemia (AML) remains unknown. To search the association between lncRNA SNPs and AML outcomes, thirty tagSNPs in five lncRNAs were genotyped in 313 AML patients. Survival analysis indicated that GAS5 rs558296...

journal_title：Leukemia & lymphoma

authors： Yan H,Zhang DY,Li X,Yuan XQ,Yang YL,Zhu KW,Zeng H,Li XL,Cao S,Zhou HH,Zhang W,Chen XP

更新日期：2017-08-01 00:00:00

abstract：:Several studies have indicated that age, hemoglobin and serum albumin are among the most important prognostic factors for survival of patients with Waldenstrom's macroglobulinemia (WM). Furthermore, recent data indicate that serum b2-microglobulin may be also significant. The recently proposed International Staging Sy...

journal_title：Leukemia & lymphoma

authors： Dimopoulos M,Gika D,Zervas K,Kyrtsonis M,Symeonidis A,Anagnostopoulos A,Bourantas K,Matsouka C,Pangalis G

更新日期：2004-09-01 00:00:00

abstract：:We retrospectively studied the prevalence of C1 esterase inhibitor (C1 INH) deficiency in 131 patients with various lymphomas. We determined C1 INH activity, C1 INH antigen, and C4 concentration at diagnosis and after chemotherapy. In follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocy...

journal_title：Leukemia & lymphoma

authors： Bekos C,Perkmann T,Krauth M,Raderer M,Lechner K,Jaeger U

更新日期：2016-09-01 00:00:00

abstract：:Despite individual differences between certain leukemias, the overall survival rate in acute leukemia remains low at approximately 40%. Novel therapeutics, including targeted therapies like tyrosine kinase inhibitors, have been incorporated into treatment regimens, but most have failed at eradicating leukemic stem cel...

journal_title：Leukemia & lymphoma

authors： Karantanou C,Godavarthy PS,Krause DS

更新日期：2018-11-01 00:00:00

abstract：:In order to survive, cells need tight control of cell cycle progression. The control mechanisms are often lost in human cancer cells. The cell cycle is driven forward by cyclin-dependent kinases (CDKs). The CDK inhibitors (CKIs) are important regulators of the CDKs. As the name implies, CKIs were initially shown to ne...

journal_title：Leukemia & lymphoma

authors： Møller MB

更新日期：2000-09-01 00:00:00

abstract：:The association of chronic lymphocytic leukemia (CLL) with essential thrombocythemia (ET) is an extremely rare event and until now 3 patients with such coexistence have been reported in the literature. We report a 77-year-old white woman in whom these two disorders were diagnosed concomitantly on the basis of peripher...

journal_title：Leukemia & lymphoma

authors： Robak T,Urbańska-Ryś H,Góra-Tybor J,Wawrzyniak E,Korycka A,Bartkowiak J,Kordek R,Polliack A

更新日期：2003-08-01 00:00:00

abstract：:The overall cure rate of adults with newly-diagnosed acute myelogenous leukemia (AML) treated with continuous infusion high-dose cytarabine (CIHDAC) is comparable to that with standard-dose ara-C plus anthracycline or amsacrine (AMSA). We tested whether the addition of AMSA to CIH-DAC improves the outcome of adults wi...

journal_title：Leukemia & lymphoma

authors： Ghaddar HM,Pierce S,Kantarjian HM,Freireich EJ,Keating MJ,Estey EH

更新日期：1996-06-01 00:00:00

abstract：:Autocrine Motility Factor (AMF)/maturation factor (MF)/neuroleukin (NLK) is a multifunctional protein, which acts as a glucose 6-phosphate isomerase (G6PI) intracellularly. Exto-G6PI stimulates invasion and metastasis of tumor cells, neurotropic growth and differentiation of leukemic cells. The cell motility and proli...

journal_title：Leukemia & lymphoma

authors： Haga A,Komazaki S,Funasaka T,Hashimoto K,Yokoyama Y,Watanabe H,Raz A,Nagase H

更新日期：2006-10-01 00:00:00

abstract：:In acute myeloid leukemia (AML), cytogenetics predicts treatment outcome for the favorable and poor subgroups but not for the intermediate subgroup. Polymorphisms within the nucleotide excision repair (NER) pathway may lead to interindividual differences in DNA repair capacity, influencing outcome. We studied the role...

journal_title：Leukemia & lymphoma

authors： Strom SS,Estey E,Outschoorn UM,Garcia-Manero G

更新日期：2010-04-01 00:00:00

abstract：:Apoptosis, the caspase-mediated cell death, plays an important role in the etiology, pathogenesis and therapy of a variety of diseases. Abnormalities of apoptosis regulation, resulting in either its inhibition or enhancement, play a key role in the development of various malignant hematological disorders. Several rout...

journal_title：Leukemia & lymphoma

authors： Smolewski P,Darzynkiewicz Z,Robak T

更新日期：2003-07-01 00:00:00

abstract：:Venocclusive disease of the liver (VOD) is one of the most common and serious complications following stem cell transplantation. High-dose chemotherapy or chemoradiotherapy injures the structures of Zone 3 of the liver acinus and produces the clinical syndrome of hepatomegaly or right upper quadrant pain, jaundice, an...

journal_title：Leukemia & lymphoma

authors： Richardson P,Bearman SI

更新日期：1998-10-01 00:00:00

abstract：:Angiogenesis is a necessary step in solid tumor progression (growth, invasion and metastasis) with which it correlates and is indicative of an unfavourable prognosis. We observed bone marrow angiogenesis in patients with active multiple myeloma (MM), though not in patients with non-active MM nor with monoclonal gammop...

journal_title：Leukemia & lymphoma

authors： Vacca A,Ribatti D,Roncali L,Dammacco F

更新日期：1995-12-01 00:00:00

abstract：:We evaluated outcome of 235 primary treatment failure (PTF) diffuse large B-cell lymphoma (DLBCL) patients based on salvage chemotherapy regimen and putative cell-of-origin (COO). Patients were divided into two groups; group A (n = 38) received high-dose cytarabine containing regimen, either DHAP or ESHAP. Patients in...

journal_title：Leukemia & lymphoma

authors： Badar T,Hamadani M,Bachanova V,Maddocks KJ,Umyarova E,Chavez JC,Epperla N,Chhabra S,Xavier AC,Karmali R,Salhab M,Reddy N,Glenn MJ,Hernandez-Ilizaliturri FJ,Flowers CR,Evens AM,Zhou Z,Lansigan F,Barta SK,Cohen JB,F

更新日期：2019-04-01 00:00:00

abstract：:Colony stimulating factors reduce the duration of neutropenia following intensive chemotherapy in a variety of settings, but the advantages in the management of leukemia are inconclusive. The variations in clinical results and the high costs of granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage c...

journal_title：Leukemia & lymphoma

authors： Bennett CL,Stinson TJ,Laver JH,Bishop MR,Godwin JE,Tallman MS

更新日期：2000-03-01 00:00:00

abstract：:Few reports on the successful treatment of T-cell large granular lymphocyte (LGL) leukemia with the humanized anti-CD52 monoclonal antibody alemtuzumab are emerging in the literature. The expression of CD52 by LGLs has not been previously investigated. Using semi-quantitative 2- and 3-color flow cytometry, we document...

journal_title：Leukemia & lymphoma

authors： Osuji N,Del Giudice I,Matutes E,Morilla A,Owusu-Ankomah K,Morilla R,Dunlop A,Catovksy D

更新日期：2005-05-01 00:00:00

abstract：:One hundred and ninety-six untreated de novo acute myeloid leukemia (AML) patients were treated with homoharringtonine + cytosine arabinoside (HA) based induction therapy composed of three chemotherapeutic drugs (HAD/M, D-daunorubicin-DNR, M-mitozantrone-MTZ) used in our hospital for the past 12 years. The patient pop...

journal_title：Leukemia & lymphoma

authors： Mi Y,Xue Y,Yu W,Liu S,Zhao Y,Meng Q,Bian S,Wang J

更新日期：2008-03-01 00:00:00